A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.
|Articles|December 1, 2007
Supplements and Featured Publications
- Report from the Roundtable: Progress and Opportunities in the Managed Care of Dementia
- Volume 13
- Issue 8 Suppl
Frequently Asked Questions and Answers for Long-term Care Healthcare Professionals
Advertisement
Articles in this issue
almost 19 years ago
Participating Facultyalmost 19 years ago
Introductionalmost 19 years ago
The Burden of Dementiaalmost 19 years ago
Current Issues in Dementia Pharmacotherapyalmost 19 years ago
Current Implications for the Managed Care of Dementiaalmost 19 years ago
CME/CE PosttestAdvertisement
Related to this article
ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5